Endo Pharma Reports Encouraging Phase 2 Data From XIAFLEX Study - Quick Facts

(RTTNews) - Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP, ENL.TO) reported new data evaluating the safety and efficacy of XIAFLEX (collagenase clostridium histolyticum) injection under investigation for the treatment of palmar Dupuytren's disease nodules. In a Phase 2 placebo-controlled, dose-ranging study, in 75 adult study participants with Dupuytren's disease and at least 1 nodule who received a single injection of CCH 0.40 mg or 0.60 mg, a statistically significant decrease was shown from baseline in the mean nodule surface area, consistency score and hardness score at week 8 versus study participants receiving placebo.

Sue Hall, Endo's EVP, Chief Scientific Officer and Global Head of Research & Development and Quality, stated: "We are encouraged that these new data showed a beneficial effect for patients with Dupuytren's nodules and the potential for improvement in symptoms and discomfort. We continue to be excited by these data and other potential indications for XIAFLEX."